(Q83656106)
Statements
Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience (English)
W S Harmsen
A R Zinsmeister
S V Kane
S Horst
W J Sandborn
B Becker
B Neis
M Moscandrew
K A Hanson
W J Tremaine
D H Bruining
W A Faubion